SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending amidst a turbulent period, primarily driven by the contentious Warner Bros. Discovery acquisition saga and a competing bid from Paramount Skydance. Community sentiment is notably divided, with many investors expressing concern over the deal's potential debt implications and regulatory scrutiny, while others view the stock's significant downturn as an oversold opportunity ahead of its anticipated Q4 earnings report.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending due to reports of a Department of Justice probe into Fed Chair Jerome Powell, which many perceive as political pressure to influence interest rates and undermine the Federal Reserve's independence. The community is sharply divided, with some fearing significant market instability and a loss of investor confidence, while others express support for the action against Powell, leading to widespread anticipation of heightened volatility and potential market declines.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is experiencing significant volatility amid intensified competition, as Amazon Pharmacy now offers a popular weight loss pill, alongside a recent downgrade by Bank of America citing lofty 2026 estimates. This combination has ignited a fierce debate among investors, with many bears predicting further declines and questioning the company's competitive moat, while bulls highlight institutional holding, international expansion, and the potential for a short squeeze based on Hims' long-term vision in personalized healthcare.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is experiencing significant volatility as a new manufacturing partnership to boost production and margins clashes with concerns over a recently announced private placement and warrants priced at a lower exercise value. The community is hotly debating whether the stock's low float will ignite a sustained short squeeze reminiscent of other recent runners or if imminent dilution will lead to a substantial price correction.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is trending after impressive CES demonstrations showcased its advanced agentic and voice AI solutions, including new partnerships with TomTom for automotive navigation and Richtech Robotics. Enthusiastic bulls anticipate a major rally and short squeeze, citing the company's innovative technology and growing client base as key differentiators against broader market skepticism and perceived price suppression. The conversation centers on SoundHound's potential as a specialized leader in the rapidly expanding conversational AI market, offering unique privacy-focused enterprise solutions.

Rich Sparkle Holdings Ltd. engages in the provision of financial printing and corporate services. The firm offers typesetting, proofreading, translation, design, and printing of listing documents, financial reports, fund documents, circulars, and announcements. It also delivers advisory services, such as conducting internal control assessment and environmental, social and governance performance evaluation, and other services including provision of co-working space. The company was founded in 2016 and is headquartered in Hong Kong.

Rich Sparkle Holdings Ltd.

Rich Sparkle Holdings Limited

Rich Sparkle Holdings (ANPA) is trending following its acquisition of TikTok icon Khaby Lame's core company and a significant private placement. This has ignited highly speculative interest and intense volatility, with many in the community anticipating a substantial short squeeze reminiscent of other recent low-float Hong Kong-based surges. Conversely, significant skepticism remains around the company's valuation and the long-term sustainability of the price action.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

Invesco QQQ Trust is trending amid significant market uncertainty following reports of a criminal investigation into Federal Reserve Chair Jerome Powell by the Department of Justice. The community is actively debating the implications of this unprecedented political pressure on Fed independence, with many bracing for increased volatility in technology and growth stocks. While some view it as a fleeting political maneuver, others express deep concern about its potential impact on monetary policy and market stability.

SSgA Active Trust - SPDR Dow Jones Industrial Average ETF

The SPDR Dow Jones Industrial Average ETF is trending as a criminal probe into Federal Reserve Chair Jerome Powell by the Department of Justice fuels intense community debate about the central bank's independence and future monetary policy. Investors are closely monitoring the market's reaction, anticipating heightened volatility and reevaluating broader economic stability in light of these significant political developments affecting key sectors like financials.

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Abivax - ADR

Abivax is surging on widespread speculation surrounding a potential acquisition by Eli Lilly, with reports from French media and government indicating broader big pharma interest in its promising ulcerative colitis treatment, obefazimod. The community is actively debating potential buyout valuations and the underlying strength of its Phase 3 data, fueling significant options activity amidst an active biotech M&A landscape.

Exxon Mobil Corp. engages in the exploration, development, and distribution of oil, gas, and petroleum products. It operates through the following segments: Upstream, Energy Products, Chemical Products, and Specialty Products. The Upstream segment organizes the exploration of crude oil and natural gas. The Energy Products segment includes fuels, aromatics, and catalyst and licensing. The Chemical Products segment offers petrochemicals. The Specialty Products segment provides finished lubricants, basestocks and waxes, synthetics, and elastomers and resins. The company was founded by John D. Rockefeller in 1882 and is headquartered in Spring, TX.

Exxon Mobil Corp.

Exxon Mobil Corp

ExxonMobil is trending as market discussion heats up following the capture of Venezuela's former President, with former President Trump signaling potential US oil company involvement in the nation's vast reserves. While many anticipate significant opportunities for XOM, a vocal segment of the community remains skeptical, pointing to the company's CEO who previously deemed Venezuela "uninvestable" due to past asset seizures and political instability. The community is actively debating the feasibility of large-scale investment and its long-term impact on global oil supply and ExxonMobil's future prospects.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CNC Deepens Medicaid Strategy With Cityblock Partnership in Illinois

Centene expands its Medicaid strategy by partnering with Cityblock Health to serve 10,000 Illinois members with 24/7 wrap-around care.

Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics

Soleno Therapeutics leads a rebound in small drug stocks as innovation, pipeline progress and M&A activity fuel optimism for 2026.

Select Medical Expands Rehab Footprint Through Vibra Healthcare JV

SEM teams up with Vibra Healthcare to run a 76-bed rehab hospital in Southern Kentucky, expanding its post-acute care footprint through a capital-efficient JV.

5 Small Drug Stocks to Buy as Industry Recovery Picks Up

Innovation is at its peak in the Zacks Medical-Drugs industry. SLNO, NKTR, RIGL, IRWD and MRKR may prove to be good additions to one's portfolio.

Rigel Pharmaceuticals (NASDAQ:RIGL) Stock Rating Upgraded by Zacks Research

Zacks Research raised shares of Rigel Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Monday...

Best Momentum Stocks to Buy for January 6th

RIGL, CM and NMTC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 6th, 2026.

New Strong Buy Stocks for January 6th

ILPT, NMTC, RIGL, RIO and BHP have been added to the Zacks Rank #1 (Strong Buy) List on January 6th, 2026.

Rigel Pharmaceuticals, Inc. $RIGL Shares Sold by Voya Investment Management LLC

Voya Investment Management LLC lowered its stake in shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) by 53.2% during the third quarter, according to the company in its most recent...

Pacer Advisors Inc. Buys New Position in Rigel Pharmaceuticals, Inc. $RIGL

Pacer Advisors Inc. bought a new position in shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) during the third quarter, according to its most recent Form 13F filing with the...

Range Financial Group LLC Makes New Investment in Rigel Pharmaceuticals, Inc. $RIGL

Range Financial Group LLC purchased a new position in shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) in the third quarter, according to its most recent disclosure with the SEC. The...

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Rigel Pharmaceuticals

Yes — Rates Move Meaningfully Lower

Short-Term Dip, No Lasting Impact

No — Mostly Political Noise

Other – Comment Below

President Trump says he’s directing $200 billion into mortgage bond purchases to bring down rates and improve housing affordability. With questions around execution, authority, and real market impact, do you think this move will actually lower mortgage rates in 2026?

Will Trump’s Mortgage Bond Plan Actually Lower Rates in 2026?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	$1.06	--	--	N/A
Q3 '25	$0.90	$1.46	62.27%	BEAT
Q2 '25	$2.58	$3.28	27.13%	BEAT
Q1 '25	$0.09	$0.63	605.80%	BEAT
Q4 '24	$0.45	$0.80	77.48%	BEAT

RIGL
Rigel Pharmaceuticals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest RIGL News

RIGLRigel Pharmaceuticals